NexPlasmaGen Secures Patent in South Korea | NexPlasmaGen
17289
post-template-default,single,single-post,postid-17289,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

NexPlasmaGen Secures Patent in South Korea

24 Jul NexPlasmaGen Secures Patent in South Korea

Posted at 15:12h in Uncategorized by
0 Likes

Montreal / July 24, 2025 – NexPlasmaGen is proud to announce that it has secured a patent in South Korea to protect its Convertible Plasma Jet (CPJ) technology for breast cancer treatment.

The patent application number in the Republic of Korea is No. 10-2022-7001947. This patent marks a significant milestone in safeguarding NexPlasmaGen’s intellectual property in Asia. In addition to the same patent already granted in Japan, the patent granted in South Korea will enable the company, in the medium term, to commercialize its CPJ medical device in Asia.

ABOUT NEXPLASMAGEN

NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. The use of its patented cold plasma medical device will improve patient outcomes in breast conserving therapy.

Contact

Valérie Léveillé, CEO/Founder

1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/

No Comments

Post A Comment